RIDE, NERV and GNLN among pre-market losers

seekingalpha2023-06-29

BioXcel Therapeutics (BTAI) -67% announces positive topline results from TRANQUILITY II phase 3 trial of BXCL501 for acute treatment of alzheimer’s disease-related agitation. CorMedix (CRMD) -21% on ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2347339464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-06-29 20:47","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2347339464","market":"us","top_or_hot":-1,"title":"RIDE, NERV and GNLN among pre-market losers","media":"seekingalpha","content":"<div>\n<p>BioXcel Therapeutics (BTAI) -67% announces positive topline results from TRANQUILITY II phase 3 trial of BXCL501 for acute treatment of alzheimer’s disease-related agitation.\nCorMedix (CRMD) -21% on ...</p>\n\n<a href=\"https://seekingalpha.com/news/3984073-ride-nerv-and-gnln-among-pre-market-losers\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIDE, NERV and GNLN among pre-market losers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIDE, NERV and GNLN among pre-market losers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-06-29 20:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3984073-ride-nerv-and-gnln-among-pre-market-losers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioXcel Therapeutics (BTAI) -67% announces positive topline results from TRANQUILITY II phase 3 trial of BXCL501 for acute treatment of alzheimer’s disease-related agitation.\nCorMedix (CRMD) -21% on ...</p>\n\n<a href=\"https://seekingalpha.com/news/3984073-ride-nerv-and-gnln-among-pre-market-losers\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://seekingalpha.com/news/3984073-ride-nerv-and-gnln-among-pre-market-losers","article_id":"2347339464","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2347339464","pubTimestamp":1688042844,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"BioXcel Therapeutics  -67%announces positive topline results from TRANQUILITY II phase 3 trial of BXCL501 for acute treatment of alzheimer’s disease-related agitation.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CNTG":"Centogene B.V.","BK4159":"经销商","BTAI":"Bioxcel Therapeutics Inc.","BK4099":"汽车制造商","BK4196":"保健护理服务","NERV":"Minerva Neurosciences","HKIT":"海天网络","GNLN":"Greenlane Holdings Inc.","BK4557":"大麻股","BK4134":"信息科技咨询与其它服务","BDTX":"Black Diamond Therapeutics, Inc.","BENF":"Beneficient","CRMD":"CorMedix Inc.","BK4139":"生物科技","BK4555":"新能源车"},"translate_title":"RIDE、NERV和GNLN是盘前输家","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BENF":1,"RIDE":1,"NERV":1,"HKIT":1,"GNLN":1,"CRMD":1,"CNTG":1,"BTAI":1,"BDTX":1},"content_text":"BioXcel Therapeutics (BTAI) -67% announces positive topline results from TRANQUILITY II phase 3 trial of BXCL501 for acute treatment of alzheimer’s disease-related agitation.\nCorMedix (CRMD) -21% on pricing $40M securities offering.\nGreenlane Holdings (GNLN) -16%.\nBlack Diamond Therapeutics (BDTX) -13% on $75M stock offering.\nHitek Global (HKIT) -11%.\nCentogene (CNTG) -10%.\nMinerva Neurosciences (NERV) -10%.\nBeneficient (BENF) -7%.\nLordstown Motors (RIDE) -5%.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2347339464"}